Last reviewed · How we verify
Verapamil Injection
Verapamil blocks L-type calcium channels in cardiac and vascular smooth muscle, reducing calcium influx and slowing electrical conduction.
Verapamil blocks L-type calcium channels in cardiac and vascular smooth muscle, reducing calcium influx and slowing electrical conduction. Used for Supraventricular tachycardia (acute termination and rate control), Atrial fibrillation with rapid ventricular response, Hypertension.
At a glance
| Generic name | Verapamil Injection |
|---|---|
| Also known as | Verapamil, Calan, Isoptin |
| Sponsor | Nishtar Medical University |
| Drug class | Calcium channel blocker (non-dihydropyridine) |
| Target | L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Verapamil is a non-dihydropyridine calcium channel blocker that inhibits the inward movement of calcium ions through L-type calcium channels in the heart and blood vessels. This action decreases myocardial contractility, slows atrioventricular (AV) node conduction, and causes vasodilation, resulting in reduced heart rate, blood pressure, and cardiac workload.
Approved indications
- Supraventricular tachycardia (acute termination and rate control)
- Atrial fibrillation with rapid ventricular response
- Hypertension
- Angina pectoris
Common side effects
- Constipation
- Dizziness
- Headache
- Hypotension
- Bradycardia
- Fatigue
- Edema
Key clinical trials
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- Comparison of Intralesional Triamcinolone Acetonide Treatment With Intralesional Verapamil Hydrochloride in Keloids (NA)
- The Intra-arterial Vasospasm Trial (PHASE4)
- Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment (PHASE4)
- Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients (PHASE3)
- DIstal vs Proximal Radial Artery Access for Cath (NA)
- The EPIVER Randomized Controlled Trial (NA)
- Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Verapamil Injection CI brief — competitive landscape report
- Verapamil Injection updates RSS · CI watch RSS
- Nishtar Medical University portfolio CI